Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy

European Heart Journal

Volumn 34, Issue 32, 2013, Pages 2529-2537

  Coats, Caroline J ^a   Gallagher, Mathew J ^b   Foley, Michael ^c   O'Mahony, Constantinos ^a   Critoph, Christopher ^a   Gimeno, Juan ^d   Dawnay, Anne ^b   McKenna, William J ^a,b   Elliott, Perry M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Brain natriuretic peptide; Heart failure; Hypertrophic cardiomyopathy; Prognosis; Risk stratification

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE; VERAPAMIL; WARFARIN;

ADULT; AGED; ARTICLE; DEATH; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART TRANSPLANTATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCLE RESECTION; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SUDDEN DEATH;

BRAIN NATRIURETIC PEPTIDE; HEART FAILURE; HYPERTROPHIC CARDIOMYOPATHY; PROGNOSIS; RISK STRATIFICATION;

ADOLESCENT; ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84881289733     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht070     Document Type: Article

References (31)

1. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-322. (Pubitemid 36936846)
2. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004;6:257-260. (Pubitemid 38253043)
3. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167. (Pubitemid 34764819)
4. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-2397. (Pubitemid 34556391)
5. Ogino K, Ogura K, Kinugawa T, Osaki S, Kato M, Furuse Y, Kinugasa Y, Tomikura Y, Igawa O, Hisatome I, Shigemasa C. Neurohumoral profiles in patients with hypertrophic cardiomyopathy: differences to hypertensive left ventricular hypertrophy. Circ J 2004;68:444-450. (Pubitemid 38657533)
6. Pieroni M, Bellocci F, Sanna T, Verardo R, Ierardi C, Maseri A, Frustaci A, Crea F. Increased brain natriuretic peptide secretion is a marker of disease progression in nonobstructive hypertrophic cardiomyopathy. J Card Fail 2007;13: 380-388. (Pubitemid 46977788)
7. Arteaga E, Araujo AQ, Buck P, Ianni BM, Rabello R, Mady C. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomy-opathy. Am Heart J 2005;150:1228-1232. (Pubitemid 41773527)
8. Kaski JP, Tomé-Esteban MT, Mead-Regan S, Pantazis A, Marek J, Deanfield JE, McKenna WJ, Elliott PM. B-Type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy. Heart 2008;94:1307-1311.
9. Maron BJ, Tholakanahalli VN, Zenovich AG, Casey SA, Duprez D, Aeppli DM, Cohn JN. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 2004;109: 984-989. (Pubitemid 38282851)
10. Thaman R, Esteban MT, Barnes S, Gimeno JR, Mist B, Murphy R, Collinson PO, McKenna WJ, Elliott PM. Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 2006;98:515-519. (Pubitemid 44162879)
11. Payá E, Marín F, González J, Gimeno JR, Feliu E, Romero A, Ruiz-Espejo F, Roldán V, Climent V, de la Morena G, Valdés M. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomy-opathy: clinical implications. J Card Fail 2008;14:414-419. (Pubitemid 351749840)
12. Binder J, Ommen SR, Chen HH, Ackerman MJ, Tajik AJ, Jaffe AS. Usefulness of brain natriuretic peptide levels in the clinical evaluation of patients with hypertrophic cardiomyopathy. Am J Cardiol 2007;100:712-714. (Pubitemid 47223150)
13. McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 1997;77:130-132. (Pubitemid 27115795)
14. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93:841-842. (Pubitemid 26074816)
15. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976;37:7-11.
16. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-303. (Pubitemid 36119984)
17. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124:2761-2796.
18. Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33: 2044-2051.
19. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96: 2987-2991. (Pubitemid 27500099)
20. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1-S266.
21. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-663. (Pubitemid 38364624)
22. Wiese S, Breyer T, Dragu A, Wakili R, Burkard T, Schmidt-Schweda S, Füchtbauer EM, Dohrmann U, Beyersdorf F, Radicke D, Holubarsch CJ. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 2000;102:3074-3079.
23. Nakamura T, Sakamoto K, Yamano T, Kikkawa M, Zen K, Hikosaka T, Kubota T, Azuma A, Nishimura T. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:1657-1663. (Pubitemid 34494290)
24. Nishigaki K, Tomita M, Kagawa K, Noda T, Minatoguchi S, Oda H, Watanabe S, Morita N, Nakao K, Fujiwara H. Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1996;28:1234-1242. (Pubitemid 26377000)
25. Honda T, Shono H, Koyama J, Tsuchiya T, Hayashi M, Hirayama T, Uesugi H, Honda T. Impact of right atrial-left ventricular dual-chamber permanent pacing in patients with severely symptomatic hypertrophic obstructive cardiomyopathy. Circ J 2005;69:536-542. (Pubitemid 40745726)
26. Kubo T, Kitaoka H, Okawa M, Yamanaka S, Hirota T, Baba Y, Hayato K, Yamasaki N, Matsumura Y, Yasuda N, Sugiura T, Doi YL. Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy. Circ J 2011;75:919-926.
27. Mutlu B, Bayrak F, Kahveci G, Degertekin M, Eroglu E, Basaran Y. Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy. Am J Cardiol 2006;98:1504-1506. (Pubitemid 44779482)
28. Kitaoka H, Kubo T, Okawa M, Takenaka N, Sakamoto C, Baba Y, Hayashi K, Yamasaki N, Matsumura Y, Doi YL. Tissue Doppler imaging and plasma BNP levels to assess the prognosis in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiography 2011;24:1020-1025.
29. Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev 2007;12:23-36. (Pubitemid 46629244)
30. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J 2012;33: 1787-1847.
31. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, Udelson JE, Cecchi F, Maron BJ. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46:480-487. (Pubitemid 41040290)